4//SEC Filing
Babu Yarlagadda S 4
Accession 0001127602-20-007672
CIK 0000882796other
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 4:42 PM ET
Size
5.4 KB
Accession
0001127602-20-007672
Insider Transaction Report
Form 4
Babu Yarlagadda S
VP Drug Discovery
Transactions
- Award
Emp. Stock Option (Right to Buy)
2020-02-21+18,000→ 18,000 totalExercise: $11.13From: 2020-02-21Exp: 2024-12-22→ Common Stock (18,000 underlying)
Footnotes (1)
- [F1]On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested.
Documents
Issuer
BIOCRYST PHARMACEUTICALS INC
CIK 0000882796
Entity typeother
Related Parties
1- filerCIK 0001452635
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 4:42 PM ET
- Size
- 5.4 KB